Drug Trial Radar · NCT07948005
A Long-Term Follow-Up Study of Subjects With Stargardt Disease (STGD1) Treated With SB-007
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
55
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Dec 31, 2035
Study completion Dec 31, 2035
Sponsor
- Lead sponsor
- Splice BioIndustry
- Sponsor type
- Industry
- First posted
- Nov 19, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the long-term safety of subretinal SB-007 administration in subjects with Stargardt Disease Type 1 (STGD1). This is a multicenter study which will follow subjects over a 164-week period after completion of an antecedent SB-007 interventional trial.
Conditions
- Stargardt Disease
- Stargardt Macular Degeneration
- Stargardt Macular Dystrophy
Interventions
No new interventionDrug
This is an observational long-term follow-up (LTFU) study of subjects with STGD1 who were previously treated with SB-007 in an antecedent SB-007 interventional trial. There is no new intervention involved in this LTFU study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Long-term safety of SB-007Time frame: 164 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.